{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T18:22:16Z","timestamp":1788546136459,"version":"build-2803163510"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,3,18]],"date-time":"2019-03-18T00:00:00Z","timestamp":1552867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,3,18]],"date-time":"2019-03-18T00:00:00Z","timestamp":1552867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001333","name":"Rhodes University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001333","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001322","name":"South African Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>According to the 2018 report of the United Nations Programme on HIV\/AIDS (UNAIDS), acquired immune deficiency syndrome (AIDS), a disease caused by the human immunodeficiency virus (HIV), remains a significant public health problem. The non-existence of a cure or effective vaccine for the disease and the associated emergence of resistant viral strains imply an urgent need for the discovery of novel anti-HIV drug candidates. The current study aimed to identify potential anti-retroviral compounds from<jats:italic>Alchornea cordifolia<\/jats:italic>. Bioactive compounds were identified using several chromatographic and spectroscopic techniques and subsequently evaluated for cytotoxicity and anti-HIV properties. Molecular modelling studies against HIV-1 integrase (HIV-1 IN) were performed to decipher the mode of action of methylgallate, the most potent compound (IC<jats:sub>50<\/jats:sub>\u2009=\u20093.7\u2009nM) and its analogues from ZINC database. Cytotoxicity assays showed that neither the isolated compounds nor the crude methanolic extract displayed cytotoxicity effects on the HeLa cell line. A strong correlation between the<jats:italic>in vitro<\/jats:italic>and<jats:italic>in silico<\/jats:italic>results was observed and important HIV-1 IN residues interacting with the different compounds were identified. These current results indicate that methylgallate is the main anti-HIV-1 compound in<jats:italic>A. cordifolia<\/jats:italic>stem bark, and could be a potential platform for the development of new HIV-1 IN inhibitors.<\/jats:p>","DOI":"10.1038\/s41598-019-41403-x","type":"journal-article","created":{"date-parts":[[2019,3,19]],"date-time":"2019-03-19T18:46:13Z","timestamp":1553021173000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Anti-HIV-1 integrase potency of methylgallate from Alchornea cordifolia using in vitro and in silico approaches"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8667-8351","authenticated-orcid":false,"given":"Xavier","family":"Siwe-Noundou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thommas M.","family":"Musyoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vuyani","family":"Moses","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek T.","family":"Ndinteh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dumisani","family":"Mnkandhla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinrich","family":"Hoppe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6861-7849","authenticated-orcid":false,"given":"\u00d6zlem","family":"Tastan Bishop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui W. M.","family":"Krause","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,18]]},"reference":[{"key":"41403_CR1","doi-asserted-by":"publisher","first-page":"34","DOI":"10.2174\/1874613601610010034","volume":"10","author":"ABM Kharsany","year":"2016","unstructured":"Kharsany, A. B. M. & Karim, Q. A. HIV Infection and AIDS in Sub-Saharan Africa: Current Status, Challenges and Opportunities. Open. AIDS J. 10, 34\u201348 (2016).","journal-title":"AIDS J."},{"key":"41403_CR2","doi-asserted-by":"publisher","first-page":"S106","DOI":"10.1093\/cid\/cix1139","volume":"66","author":"N Ford","year":"2018","unstructured":"Ford, N. et al. Managing Advanced HIV Disease in a Public Health Approach. Clin. Infect. Dis. 66, S106\u2013SS110 (2018).","journal-title":"Clin. Infect. Dis."},{"key":"41403_CR3","unstructured":"UNAIDS data 2018."},{"key":"41403_CR4","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/imr.12066","volume":"254","author":"AA Okoye","year":"2013","unstructured":"Okoye, A. A. & Picker, L. J. CD4(+) T-cell depletion in HIV infection: mechanisms of immunological failure. Immunol. Rev. 254, 54\u201364 (2013).","journal-title":"Immunol. Rev."},{"key":"41403_CR5","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1093\/infdis\/jiw086","volume":"214","author":"H Furrer","year":"2016","unstructured":"Furrer, H. Opportunistic Diseases During HIV Infection\u2014Things Aren\u2032t What They Used to Be, or Are They? J. Infect. Dis. 214, 830\u2013831 (2016).","journal-title":"J. Infect. Dis."},{"key":"41403_CR6","doi-asserted-by":"publisher","first-page":"154","DOI":"10.20411\/pai.v1i1.133","volume":"1","author":"MM Lederman","year":"2016","unstructured":"Lederman, M. M. et al. A Cure for HIV Infection: \u201cNot in My Lifetime\u201d or \u201cJust Around the Corner\u201d? Pathog. Immun. 1, 154\u2013164 (2016).","journal-title":"Pathog. Immun."},{"key":"41403_CR7","first-page":"298","volume":"5","author":"R Granich","year":"2010","unstructured":"Granich, R. et al. Highly active antiretroviral treatment as prevention of HIV transmission: review of scientific evidence and update. Curr. Opin. HIV AIDS 5, 298\u2013304 (2010).","journal-title":"HIV AIDS"},{"key":"41403_CR8","unstructured":"FDA-Approved HIV Medicines | Understanding HIV\/AIDS | AIDSinfo. Available at: https:\/\/aidsinfo.nih.gov\/understanding-hiv-aids\/fact-sheets\/21\/58\/fda-approved-hiv-medicines (Accessed: 24th September 2018)."},{"key":"41403_CR9","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.antiviral.2013.01.007","volume":"98","author":"L Men\u00e9ndez-Arias","year":"2013","unstructured":"Men\u00e9ndez-Arias, L. Molecular basis of human immunodeficiency virus type 1 drug resistance: Overview and recent developments. Antiviral Res. 98, 93\u2013120 (2013).","journal-title":"Antiviral Res."},{"key":"41403_CR10","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1517\/14656566.2010.509345","volume":"12","author":"RK Ghosh","year":"2011","unstructured":"Ghosh, R. K., Ghosh, S. M. & Chawla, S. Recent advances in antiretroviral drugs. Expert Opin. Pharmacother. 12, 31\u201346 (2011).","journal-title":"Expert Opin. Pharmacother."},{"key":"41403_CR11","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3389\/fimmu.2013.00337","volume":"4","author":"J Zhang","year":"2013","unstructured":"Zhang, J. & Crumpacker, C. Eradication of HIV and Cure of AIDS, Now and How? Front. Immunol. 4, 337 (2013).","journal-title":"Front. Immunol."},{"key":"41403_CR12","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.coph.2010.04.011","volume":"10","author":"ED Clercq","year":"2010","unstructured":"Clercq, E. D. Antiretroviral drugs. Curr. Opin. Pharmacol. 10, 507\u2013515 (2010).","journal-title":"Curr. Opin. Pharmacol."},{"key":"41403_CR13","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1089\/apc.2007.0093","volume":"22","author":"N Kumarasamy","year":"2008","unstructured":"Kumarasamy, N. et al. Spectrum of Adverse Events After Generic HAART in Southern Indian HIV-Infected Patients. AIDS Patient Care STDS 22, 337\u2013344 (2008).","journal-title":"AIDS Patient Care STDS"},{"key":"41403_CR14","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1093\/infdis\/jiw491","volume":"214","author":"K Steegen","year":"2016","unstructured":"Steegen, K. et al. Prevalence of antiretroviral drug resistance in patients who are not responding to protease inhibitor-based treatment: Results from the first national survey in South Africa. J. Infect. Dis. 214, 1826\u20131830 (2016).","journal-title":"J. Infect. Dis."},{"key":"41403_CR15","doi-asserted-by":"crossref","unstructured":"Hickmans, A. B., Palmer, I., Engelmans, A., Craigies, R. & Wingfieldon, P. Biophysical and Enzymatic Properties of the Catalytic Domain of HIV-1 Integyase*. The Journal Of Biological Chemistry 269 (1994).","DOI":"10.1016\/S0021-9258(19)62042-9"},{"key":"41403_CR16","doi-asserted-by":"publisher","first-page":"979","DOI":"10.2174\/1568026043388448","volume":"4","author":"NJ Anthony","year":"2004","unstructured":"Anthony, N. J. HIV-1 integrase: a target for new AIDS chemotherapeutics. Curr. Top. Med. Chem. 4, 979\u201390 (2004).","journal-title":"Curr. Top. Med. Chem."},{"key":"41403_CR17","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S0167-7799(97)01016-0","volume":"15","author":"M Thomas","year":"1997","unstructured":"Thomas, M. & Brady, L. HIV integrase: a target for AIDS therapeutics. Trends Biotechnol. 15, 167\u201372 (1997).","journal-title":"Trends Biotechnol."},{"key":"41403_CR18","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/nsb0797-567","volume":"4","author":"M Cai","year":"1997","unstructured":"Cai, M. et al. Solution structure of the N-terminal zinc binding domain of HIV-1 integrase. Nat. Struct. Biol. 4, 567\u201377 (1997).","journal-title":"Nat. Struct. Biol."},{"key":"41403_CR19","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1126\/science.7801124","volume":"266","author":"F Dyda","year":"1994","unstructured":"Dyda, F. et al. Crystal structure of the catalytic domain of HIV-1 integrase: similarity to other polynucleotidyl transferases. Science 266, 1981\u20136 (1994).","journal-title":"Science"},{"key":"41403_CR20","doi-asserted-by":"publisher","first-page":"9826","DOI":"10.1021\/bi00031a002","volume":"34","author":"PJ Lodi","year":"1995","unstructured":"Lodi, P. J. et al. Solution structure of the DNA binding domain of HIV-1 integrase. Biochemistry 34, 9826\u201333 (1995).","journal-title":"Biochemistry"},{"key":"41403_CR21","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1126\/science.2171144","volume":"249","author":"FD Bushman","year":"1990","unstructured":"Bushman, F. D., Fujiwara, T. & Craigie, R. Retroviral DNA integration directed by HIV integration protein in vitro. Science 249, 1555\u20138 (1990).","journal-title":"Science"},{"key":"41403_CR22","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1073\/pnas.88.4.1339","volume":"88","author":"FD Bushman","year":"1991","unstructured":"Bushman, F. D. & Craigie, R. Activities of human immunodeficiency virus (HIV) integration protein in vitro: specific cleavage and integration of HIV DNA. Proc. Natl. Acad. Sci. USA 88, 1339\u201343 (1991).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"41403_CR23","doi-asserted-by":"crossref","first-page":"6361","DOI":"10.1128\/jvi.66.11.6361-6369.1992","volume":"66","author":"A Engelman","year":"1992","unstructured":"Engelman, A. & Craigie, R. Identification of conserved amino acid residues critical for human immunodeficiency virus type 1 integrase function in vitro. J. Virol. 66, 6361\u20139 (1992).","journal-title":"J. Virol."},{"key":"41403_CR24","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1128\/MCB.12.5.2331","volume":"12","author":"J Kulkosky","year":"1992","unstructured":"Kulkosky, J., Jones, K. S., Katz, R. A., Mack, J. P. & Skalka, A. M. Residues critical for retroviral integrative recombination in a region that is highly conserved among retroviral\/retrotransposon integrases and bacterial insertion sequence transposases. Mol. Cell. Biol. 12, 2331\u20138 (1992).","journal-title":"Mol. Cell. Biol."},{"key":"41403_CR25","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0166-3542(02)00166-3","volume":"58","author":"NK Ayisi","year":"2003","unstructured":"Ayisi, N. K. & Nyadedzor, C. Comparative in vitro effects of AZT and extracts of Ocimum gratissimum, Ficus polita, Clausena anisata, Alchornea cordifolia, and Elaeophorbia drupifera against HIV-1 and HIV-2 infections. Antiviral Res. 58, 25\u201333 (2003).","journal-title":"Antiviral Res."},{"key":"41403_CR26","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jep.2015.12.043","volume":"179","author":"X Siwe Noundou","year":"2016","unstructured":"Siwe Noundou, X., Krause, R. W. M., Van Vuuren, S. F., Ndinteh, D. T. & Olivier, D. K. Antibacterial effects of Alchornea cordifolia (Schumach. and Thonn.) M\u00fcll. Arg extracts and compounds on gastrointestinal, skin, respiratory and urinary tract pathogens. J. Ethnopharmacol. 179, 76\u201382 (2016).","journal-title":"J. Ethnopharmacol."},{"key":"41403_CR27","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jep.2007.08.043","volume":"115","author":"H Mavar-Manga","year":"2008","unstructured":"Mavar-Manga, H. et al. Anti-inflammatory compounds from leaves and root bark of Alchornea cordifolia (Schumach. & Thonn.) M\u00fcll. Arg. J. Ethnopharmacol. 115, 25\u201329 (2008).","journal-title":"J. Ethnopharmacol."},{"key":"41403_CR28","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1021\/acs.jcim.5b00559","volume":"55","author":"T Sterling","year":"2015","unstructured":"Sterling, T. & Irwin, J. J. ZINC 15 \u2013 Ligand Discovery for Everyone. J. Chem. Inf. Model. 55, 2324\u20132337 (2015).","journal-title":"J. Chem. Inf. Model."},{"key":"41403_CR29","doi-asserted-by":"publisher","first-page":"6661","DOI":"10.1073\/pnas.092056199","volume":"99","author":"JA Grobler","year":"2002","unstructured":"Grobler, J. A. et al. Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes. Proc. Natl. Acad. Sci. USA 99, 6661\u20136 (2002).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"41403_CR30","doi-asserted-by":"publisher","first-page":"13040","DOI":"10.1073\/pnas.96.23.13040","volume":"96","author":"Y Goldgur","year":"1999","unstructured":"Goldgur, Y. et al. Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design. Proc. Natl. Acad. Sci. USA 96, 13040\u20133 (1999).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"41403_CR31","doi-asserted-by":"crossref","unstructured":"Webb, B. & Sali, A. In Current Protocols in Bioinformatics 54, 5.6.1\u20135.6.37 (John Wiley & Sons, Inc., 2016).","DOI":"10.1002\/cpbi.3"},{"key":"41403_CR32","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1110\/ps.062416606","volume":"15","author":"M-Y Shen","year":"2006","unstructured":"Shen, M.-Y. & Sali, A. Statistical potential for assessment and prediction of protein structures. Protein Sci. 15, 2507\u201324 (2006).","journal-title":"Protein Sci."},{"key":"41403_CR33","doi-asserted-by":"publisher","first-page":"W407","DOI":"10.1093\/nar\/gkm290","volume":"35","author":"M Wiederstein","year":"2007","unstructured":"Wiederstein, M. & Sippl, M. J. ProSA-web: interactive web service for the recognition of errors in three-dimensional structures of proteins. Nucleic Acids Res. 35, W407\u2013W410 (2007).","journal-title":"Nucleic Acids Res."},{"key":"41403_CR34","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/S0076-6879(97)77022-8","volume":"277","author":"D Eisenberg","year":"1997","unstructured":"Eisenberg, D., L\u00fcthy, R. & Bowie, J. U. VERIFY3D: assessment of protein models with three-dimensional profiles. Methods Enzymol. 277, 396\u2013404 (1997).","journal-title":"Methods Enzymol."},{"key":"41403_CR35","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/prot.21715","volume":"71","author":"P Benkert","year":"2008","unstructured":"Benkert, P., Tosatto, S. C. E. & Schomburg, D. QMEAN: A comprehensive scoring function for model quality assessment. Proteins Struct. Funct. Bioinforma. 71, 261\u2013277 (2008).","journal-title":"Proteins Struct. Funct. Bioinforma."},{"key":"41403_CR36","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1107\/S0021889892009944","volume":"26","author":"RA Laskowski","year":"1993","unstructured":"Laskowski, R. A., MacArthur, M. W., Moss, D. S. & Thornton, J. M. PROCHECK: a program to check the stereochemical quality of protein structures. J. Appl. Crystallogr. 26, 283\u2013291 (1993).","journal-title":"J. Appl. Crystallogr."},{"key":"41403_CR37","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1002\/jcc.21256","volume":"30","author":"GM Morris","year":"2009","unstructured":"Morris, G. M. et al. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J. Comput. Chem. 30, 2785\u20132791 (2009).","journal-title":"J. Comput. Chem."},{"key":"41403_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cplett.2018.09.019","volume":"711","author":"T Musyoka","year":"2018","unstructured":"Musyoka, T., Tastan, \u00d6., Lobb, K. & Moses, V. The determination of CHARMM force fi eld parameters for the Mg 2+ containing HIV-1 integrase. Chem. Phys. Lett. 711, 1\u20137 (2018).","journal-title":"Chem. Phys. Lett."},{"key":"41403_CR39","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1002\/jcc.21287","volume":"30","author":"BR Brooks","year":"2009","unstructured":"Brooks, B. R. et al. CHARMM: The biomolecular simulation program. J. Comput. Chem. 30, 1545\u20131614 (2009).","journal-title":"J. Comput. Chem."},{"key":"41403_CR40","doi-asserted-by":"publisher","first-page":"9954","DOI":"10.1021\/jp003020w","volume":"105","author":"PM And","year":"2001","unstructured":"And, P. M. & Nilsson, L. Structure and Dynamics of the TIP3P, SPC, and SPC\/E Water Models at 298 K. J. Phys. Chem. A 105, 9954\u20139960 (2001).","journal-title":"J. Phys. Chem. A"},{"key":"41403_CR41","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1002\/jcc.23354","volume":"34","author":"J Huang","year":"2013","unstructured":"Huang, J. & MacKerell, A. D. CHARMM36 all-atom additive protein force field: Validation based on comparison to NMR data. J. Comput. Chem. 34, 2135\u20132145 (2013).","journal-title":"J. Comput. Chem."},{"key":"41403_CR42","doi-asserted-by":"publisher","first-page":"3144","DOI":"10.1021\/ci300363c","volume":"52","author":"K Vanommeslaeghe","year":"2012","unstructured":"Vanommeslaeghe, K. & MacKerell, A. D. Automation of the CHARMM General Force Field (CGenFF) I: Bond Perception and Atom Typing. J. Chem. Inf. Model. 52, 3144\u20133154 (2012).","journal-title":"J. Chem. Inf. Model."},{"key":"41403_CR43","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/jcc.21367","volume":"31","author":"K Vanommeslaeghe","year":"2010","unstructured":"Vanommeslaeghe, K. et al. CHARMM general force field: A force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields. J. Comput. Chem. 31, 671\u201390 (2010).","journal-title":"J. Comput. Chem."},{"key":"41403_CR44","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2174\/1875397300903010033","volume":"3","author":"AL Niles","year":"2009","unstructured":"Niles, A. L., Moravec, R. A. & Riss, T. L. In Vitro Viability and Cytotoxicity Testing and Same-Well Multi-Parametric Combinations for High Throughput Screening. Curr. Chem. Genomics 3, 33\u201341 (2009).","journal-title":"Curr. Chem. Genomics"},{"key":"41403_CR45","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/nrd4683","volume":"14","author":"K Katsuno","year":"2015","unstructured":"Katsuno, K. et al. Hit and lead criteria in drug discovery for infectious diseases of the developing world. Nat. Rev. Drug Discov. 14, 751\u2013758 (2015).","journal-title":"Nat. Rev. Drug Discov."},{"key":"41403_CR46","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1177\/1087057105283787","volume":"11","author":"S Miret","year":"2006","unstructured":"Miret, S., De Groene, E. M. & Klaffke, W. Comparison of In Vitro Assays of Cellular Toxicity in the Human Hepatic Cell Line HepG2. J. Biomol. Screen. 11, 184\u2013193 (2006).","journal-title":"J. Biomol. Screen."},{"key":"41403_CR47","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1110\/ps.036061.108","volume":"17","author":"D Eramian","year":"2008","unstructured":"Eramian, D., Eswar, N., Shen, M.-Y. & Sali, A. How well can the accuracy of comparative protein structure models be predicted? Protein Sci. 17, 1881\u20131893 (2008).","journal-title":"Protein Sci."},{"key":"41403_CR48","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/513481a","volume":"513","author":"J Baell","year":"2014","unstructured":"Baell, J. & Walters, M. A. Chemistry: Chemical con artists foil drug discovery. Nature 513, 481\u2013483 (2014).","journal-title":"Nature"},{"key":"41403_CR49","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1002\/ptr.5307","volume":"29","author":"S Tewtrakul","year":"2015","unstructured":"Tewtrakul, S. et al. Anti-HIV-1 Integrase Activity and Molecular Docking Study of Compounds from Caesalpinia\u2009\u2009sappan L. Phyther. Res. 29, 724\u2013729 (2015).","journal-title":"Phyther. Res."},{"key":"41403_CR50","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.2174\/0929867033456981","volume":"10","author":"C Maurin","year":"2003","unstructured":"Maurin, C., Bailly, F. & Cotelle, P. Structure-activity relationships of HIV-1 integrase inhibitors\u2013enzyme-ligand interactions. Curr. Med. Chem. 10, 1795\u2013810 (2003).","journal-title":"Curr. Med. Chem."},{"key":"41403_CR51","doi-asserted-by":"publisher","first-page":"4109","DOI":"10.1021\/jm000194t","volume":"43","author":"CA Sotriffer","year":"2000","unstructured":"Sotriffer, C. A., Ni, H. & McCammon, J. A. Active site binding modes of HIV-1 integrase inhibitors. J. Med. Chem. 43, 4109\u201317 (2000).","journal-title":"J. Med. Chem."},{"key":"41403_CR52","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1016\/S0140-6736(14)60084-2","volume":"383","author":"B Clotet","year":"2014","unstructured":"Clotet, B. et al. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet 383, 2222\u20132231 (2014).","journal-title":"Lancet"},{"key":"41403_CR53","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1056\/NEJMoa1215541","volume":"369","author":"SL Walmsley","year":"2013","unstructured":"Walmsley, S. L. et al. Dolutegravir plus Abacavir\u2013Lamivudine for the Treatment of HIV-1 Infection. N. Engl. J. Med. 369, 1807\u20131818 (2013).","journal-title":"N. Engl. J. Med."},{"key":"41403_CR54","doi-asserted-by":"publisher","first-page":"9345","DOI":"10.1021\/bi800791q","volume":"47","author":"J Marinello","year":"2008","unstructured":"Marinello, J. et al. Comparison of Raltegravir and Elvitegravir on HIV-1 Integrase Catalytic Reactions and on a Series of Drug-Resistant Integrase Mutants\u2020. Biochemistry 47, 9345\u20139354 (2008).","journal-title":"Biochemistry"},{"key":"41403_CR55","doi-asserted-by":"publisher","first-page":"10366","DOI":"10.1128\/JVI.00470-08","volume":"82","author":"O Goethals","year":"2008","unstructured":"Goethals, O. et al. Resistance Mutations in Human Immunodeficiency Virus Type 1 Integrase Selected with Elvitegravir Confer Reduced Susceptibility to a Wide Range of Integrase Inhibitors. J. Virol. 82, 10366\u201310374 (2008).","journal-title":"J. Virol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-41403-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-41403-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-41403-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T22:45:06Z","timestamp":1721083506000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-41403-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,18]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["41403"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-41403-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,18]]},"assertion":[{"value":"16 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"4718"}}